Evidence map›Paper›PMID 41301442›Full record

ReviewBiomolecules2025

Cleaving Expectations: A Review of Proteasome Functional and Catalytic Diversity.

Daniel Zachor-Movshovitz, Yegor Leushkin, Katharina I Zittlau, Gili Ben-Nissan, Michal Sharon

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel Zachor-MovshovitzDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0002-9671-2346
Yegor LeushkinDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Katharina I ZittlauDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Gili Ben-NissanDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-1913-3703
Michal SharonDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.

Funding

European Resuscitation Council AdG 101092725Israel Science Foundation 946/23
6 · The paper itself

Abstract

The proteasome is a central proteolytic complex that maintains protein homeostasis by eliminating damaged, misfolded, and regulatory proteins. Beyond this quality control role, it generates bioactive peptides that contribute to immune surveillance, intracellular signaling, neuronal communication, and antimicrobial defense. Proteolysis is mediated by the catalytic β1, β2, and β5 subunits, traditionally defined by caspase-like, trypsin-like, and chymotrypsin-like activities. However, these sites display overlapping and flexible specificities, enabling cleavage after nearly all amino acids. This review focuses on proteasome catalytic activity, with particular emphasis on the biochemical and structural features of the catalytic subunits that define cleavage selectivity. We first provide a historical overview of the discovery of proteolytic activities and trace the evolutionary diversification of subunits that gave rise to specialized variants such as the immunoproteasome, thymoproteasome, intermediate proteasomes, and the spermatoproteasome. We then highlight how advances in computational modeling and structural biology have refined our understanding of cleavage preferences. In addition, we examine how regulatory particles, post-translational modifications, and physiological conditions, including inflammation, oxidative stress, and aging, modulate proteolytic activity. Finally, we discuss the development of selective inhibitors targeting individual catalytic sites, emphasizing their therapeutic potential in cancer, autoimmunity, and infectious disease, and outline future directions for the field.

Indexed as

Proteasome Endopeptidase ComplexAnimalsCatalytic DomainHumansProtein Processing, Post-TranslationalProteolysisProteasome Endopeptidase Complexcatalytic sitesproteasomeprotein degradationprotein substrates

Identifiers

PMID41301442
PMCPMC12650242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.